News & Events

Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018

Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018     HALLE (SAALE), Germany, 22 November 2018 – Probiodrug AG (Euronext […]

Probiodrug to Attend and Present at International Conferences in November 2018

HALLE (SAALE), Germany, 29 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug publishes SAPHIR data in peer reviewed journal

SAPHIR trial data published in Alzheimer’s Research & Therapy   HALLE (SAALE), Germany, 16 October 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company […]

Probiodrug AG: Loss announcement according to §92 paragraph 1 of the German Stock Corporation Act

HALLE (SAALE), Germany, 15 October 2018 – The management board of Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to […]

Probiodrug to attend International Conferences in October 2018

HALLE (SAALE), Germany, 09 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug Reports Management Changes

HALLE (SAALE), Germany, October 5th, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announced today […]

Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy

HALLE (SAALE), Germany, 04 September, 2018: Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today […]

Probiodrug Reports Financial Results for H1 2018 and Corporate Update

HALLE (SAALE), Germany, 30 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG to Publish First Half 2018 Results on August 30, 2018

HALLE (SAALE), Germany, 23 August 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]